Stat News
WHO director-general is profoundly concerned after visit to Ebola outbreak area
The World Health Organization's director-general has declared himself profoundly concerned following a firsthand visit to the Ebola outbreak zone in the Democratic Republic of Congo. The admission signals that global health leaders view the situation as more serious than routine outbreak management. When the head of the WHO uses language that strong, the international community should be paying close attention.
Read article →Medical Xpress
Could a once-a-day pill replace weight loss injections? Phase II oral GLP-1 drug trial shows promising results
Pfizer's once-daily oral GLP-1 drug Elecoglipron has shown promising Phase II trial results, potentially offering an injection-free alternative for weight management. The small-molecule pill targets the same receptors as blockbuster drugs like Ozempic, which could dramatically expand access for patients unwilling or unable to self-inject. If late-stage trials hold up, an oral GLP-1 option would mark a significant shift in how obesity is treated at scale.
Read article →Medical Xpress
AI tool shown to reduce eye care disparities for African American adults with diabetes
African American adults with diabetes were significantly more likely to receive referrals for diabetic eye exams when screened using an AI diagnostic tool, according to researchers at Johns Hopkins' Wilmer Eye Institute. The findings, drawn from multiple community-based primary care sites, suggest AI-assisted screening can help close longstanding gaps in eye care access for underserved populations. Given that diabetic retinopathy remains a leading cause of preventable blindness, the implications for equitable healthcare delivery are substantial.
Read article →Guardian Health
Blood test can find thousands of genetic conditions in pregnancy, say scientists
A maternal blood test capable of identifying thousands of fetal genetic conditions from fragments of DNA circulating in the mother's bloodstream marks a significant leap in prenatal diagnostics. The non-invasive technique could reduce reliance on procedures such as amniocentesis, which carry a small risk of miscarriage. Researchers say the development could expand early screening options while lowering the physical risks associated with traditional testing.
Read article →Medical Xpress
FDA approves rapid-acting inhaled insulin for children
The FDA has approved Afrezza, an inhaled insulin powder, for children and adolescents aged 6 and older with type 1 or type 2 diabetes. The needle-free option marks a significant shift in pediatric diabetes management, offering a less invasive alternative to traditional injections. For young patients who struggle with daily shots, the approval could meaningfully improve treatment adherence and quality of life.
Read article →Get this delivered every morning
Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →